Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers

Inclusion Criteria

• Participants must be at least 18 years of age
• Participant must be HIV-positive and have a diagnosed malignancy. If participants are HIV-negative, they must have a newly diagnosed or recurrent malignancy that has an established scientific connection (e.g., shared etiology) to an AIDS- associated malignancy such as: * Classic Kaposi sarcoma * Transplant-associated Kaposi sarcoma * Anal cancer * Multicentric Castleman’s disease * EBV-positive lymphoma * Plasmablastic lymphoma * Hodgkin’s lymphoma
• For participants that are HIV-positive, HIV infection must be documented by means of any one of the following: * Documentation of HIV diagnosis in the medical record by a licensed health care provider * Documentation of receipt of antiretroviral therapy (ART) by a licensed health care provider (Documentation may be a record of an ART prescription in the participant’s medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant’s name. Receipt of at least two agents is required; each component agent of a multi-class combination ART regimen will be counted toward the 2-agent requirement, excepting receipt of a pre-exposure prophylaxis [PrEP] regimen alone [e.g., Truvada], which is exclusionary) * HIV ribonucleic acid (RNA) detection by a licensed HIV RNA assay demonstrating > 1000 RNA copies/mL * Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV Western blot confirmation or HIV rapid multispot antibody differentiation assay * NOTE: A “licensed” assay refers to a U.S. Food and Drug Administration (FDA)-approved assay, which is required for all investigational new drug (IND) studies
• Participants with HIV infection, regardless of participation in an AMC clinical trial, must have a diagnosis of cancer or a condition that places them at a higher risk of cancer * NOTE: Participants are not required to enroll in an AMC treatment trial to be considered eligible
• The investigator determines that the participant (or his/her legally authorized representative [LAR]) has the ability to provide informed consent and the participant or LAR provides written informed consent

Exclusion Criteria

• Donors who do not fulfill the criteria as listed above are ineligible